OncoMatch/Clinical Trials/NCT05660369
CARv3-TEAM-E T Cells in Glioblastoma
Is NCT05660369 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CARv3-TEAM-E T cells for glioblastoma.
Treatment: CARv3-TEAM-E T cells — The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: EGFR amplification
Required: EGFR egfrviii mutation
Required: EGFR wild-type
Required: MGMT unmethylated
Prior therapy
Must have received: radiation therapy — recurrent GBM
Participants must have at least received prior radiation
Cannot have received: EGFRvIII targeted therapy
Prior EGFRvIII targeted therapies
Cannot have received: bevacizumab (bevacizumab)
Prior bevacizumab treatment
Cannot have received: gene-therapy or gene-modified cellular therapy
Treatment with an any prior gene-therapy or gene-modified cellular therapy
Cannot have received: investigational agent
Participants who are receiving any other investigational agents
Cannot have received: cancer directed therapy other than radiation
Prior cancer directed therapy other than radiation is not allowed (Arm 2)
Lab requirements
Blood counts
Absolute neutrophil count ≥1,000/mcL; Platelets ≥80,000/mcL
Kidney function
CrCl ≥ 60 mL/min
Liver function
Total bilirubin ≤ institutional upper limit of normal (ULN); For patients with Gilbert's syndrome, total bilirubin can be ≤ 3xULN. AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN
Cardiac function
Left ventricular ejection fraction >50% as determined by TTE
Participants must have adequate organ and marrow function as defined below: Absolute neutrophil count ≥1,000/mcL; Platelets ≥80,000/mcL; Total bilirubin ≤ institutional upper limit of normal (ULN); For patients with Gilbert's syndrome, total bilirubin can be ≤ 3xULN. AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN; CrCl ≥ 60 mL/min; Left ventricular ejection fraction >50% as determined by TTE
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital Cancer Center · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05660369 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior EGFRvIII targeted therapy, bevacizumab, gene-therapy or gene-modified cellular therapy disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR amplification is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR egfrviii mutation is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify